נגישות
menu      
Advanced Search
Edward Averbukh, Esther Yamin, Alexey Obolensky, Eyal Banin - Ophthalmology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Ron Ofri, Raaya Ezra-Elia - Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
William Hauswirth - Department of Ophthalmology, University of Florida, Gainesville, FL

PurposeRecently, we reported on novel hereditary dayblindness in sheep caused by a mutation in the CNGA3 gene (Reicher et al., Genomics 95:101-104, 2010). Since mutations in this gene can also cause achromatopsia in humans, we decided to use these sheep as a cone-enriched, large animal model to evaluate safety and efficacy of CNGA3 gene therapy.

Powered by ClearMash Solutions Ltd -
Volcani treasures
About
Terms of use
Recovery of visual function following gene therapy in a large animal model of CNGA3 achromatopsia
54
Edward Averbukh, Esther Yamin, Alexey Obolensky, Eyal Banin - Ophthalmology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Ron Ofri, Raaya Ezra-Elia - Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
William Hauswirth - Department of Ophthalmology, University of Florida, Gainesville, FL
Recovery of visual function following gene therapy in a large animal model of CNGA3 achromatopsia

PurposeRecently, we reported on novel hereditary dayblindness in sheep caused by a mutation in the CNGA3 gene (Reicher et al., Genomics 95:101-104, 2010). Since mutations in this gene can also cause achromatopsia in humans, we decided to use these sheep as a cone-enriched, large animal model to evaluate safety and efficacy of CNGA3 gene therapy.

Scientific Publication
You may also be interested in